Eflornithine

This is a medication used to treat dark, curly hair growth on the face, particularly in women. It works by stopping the hair growth cycle. It's usually applied as a cream or solution.

Brand names:Ornidyl, Vaniqa
Medication

What people taking Eflornithine report

Every report comes from a Lived member, sent anonymously.

Have you tried Eflornithine for Hirsutism?

NameHow it went

About Eflornithine

What It's For

Eflornithine is a medicine that has been made in three very different forms, and which one a person means changes almost everything about it. Today in the US, it is mainly prescribed as Iwilfin, a tablet taken by children and adults with high-risk neuroblastoma. Neuroblastoma is a cancer that starts in immature nerve cells, most often in young children. Iwilfin is used after intensive treatment has worked at least partly, including a type of antibody treatment called anti-GD2 immunotherapy, and its goal is to lower the chance that the cancer comes back. Eflornithine was previously best known as Vaniqa, a prescription cream (13.9% strength) approved to reduce unwanted facial hair in women. FDA records now list Vaniqa as discontinued in the US, and no approved generic version of the cream is listed there, so people who used it may need to ask about other options. A third form, given by intravenous infusion, treats a late stage of one type of African sleeping sickness, a parasitic infection spread by tsetse flies. It is usually combined with another drug, nifurtimox, and is used in the countries where the disease occurs rather than in routine US care. The rest of this page focuses on the tablet and the cream.

How It Works

Eflornithine permanently blocks an enzyme called ornithine decarboxylase. This enzyme starts the body's production of polyamines, small molecules that cells need in order to grow and divide. Cells that multiply quickly, such as cancer cells and the cells at the base of a growing hair, rely heavily on this pathway. In neuroblastoma, the enzyme is switched on by MYCN, a gene that drives the growth of many of these tumors. By cutting off polyamine production, eflornithine appears to hold remaining cancer cells in a non-dividing state rather than killing them outright. That is why it is used to keep a remission from slipping, not to shrink an active tumor. On the skin, the cream is thought to block the same enzyme in hair follicles, which slows how fast facial hair grows back. It does not destroy the follicle, so the effect lasts only as long as the cream is used.

Dosage & Administration

Iwilfin tablets are taken by mouth twice a day, with or without food, for up to two years unless the cancer returns or side effects become too difficult. The dose is based on body surface area, a calculation from height and weight, so it is recalculated every three months as a child grows. Tablets can be swallowed whole, chewed, or crushed and mixed with a small amount of soft food or liquid, which helps young children. Before starting, the care team checks a blood count, liver tests and a baseline hearing test (an audiogram). If a dose is missed and the next one is less than seven hours away, the missed dose is skipped; a dose that is vomited is not repeated. The cream was applied as a thin layer to the face and the area under the chin twice a day, at least eight hours apart, and rubbed in. The area was not washed for at least four hours afterward. It was applied at least five minutes after shaving or other hair removal, and makeup or sunscreen could go on once the cream had absorbed.

Side Effects

With Iwilfin, the most common problems in studies were ear infections, diarrhea, cough, sinus and other respiratory infections, pink eye, vomiting, fever and hearing loss. Three effects need particular attention because they can become serious. Hearing loss is common and can be lasting. In studies, about 13% of patients had new or worsening hearing loss, and some needed hearing aids. Hearing is rechecked about every six months, and any new hearing trouble or ringing in the ears should be reported to the care team right away, since lowering or pausing the dose can help. Iwilfin can lower blood cell counts. Fever of 100.4°F or higher, chills, easy bruising or bleeding, blood in urine or stool, unusual tiredness or shortness of breath should be reported to the care team right away. It can also raise liver enzymes, which is usually picked up on monthly blood tests during the first six months; yellowing of the skin or eyes, dark urine, pale stools or pain under the right ribs should also be reported. The cream's side effects were mostly mild and limited to the skin: stinging, burning, tingling, redness, rash and bumps around hair follicles, especially on broken or freshly irritated skin. Using it once a day instead of twice often helped. If irritation continued, it was stopped.

Interactions & Warnings

Iwilfin can harm a developing baby, based on animal studies that showed pregnancy loss at doses similar to human doses. A pregnancy test is done before starting for anyone who could become pregnant. Females who could become pregnant, and males with partners who could, should use effective birth control during treatment and for one week after the last dose. Breastfeeding is not recommended during treatment or for one week after. The label lists no specific drug interactions, but the care team should still know about every medicine and supplement, especially during cancer care. Existing hearing problems are worth mentioning before starting, since most patients in the studies already had some hearing loss before starting. The cream was for use on the skin only, kept away from the eyes, nose and mouth, and not used by children under 12. It was not studied in pregnancy, so its use during pregnancy called for a careful conversation with the prescriber. Very little of the cream is absorbed into the body.

What to Expect

Iwilfin is a maintenance treatment taken at home over many months, alongside regular clinic visits, monthly liver tests at first, periodic blood counts and hearing checks. Its approval rests on a comparison between children who took it and similar children from an earlier study who did not, rather than a randomized trial. In that comparison, the rate of relapse, progression or death was roughly half as high in those taking eflornithine. It does not guarantee the cancer will stay away, and families often weigh its benefit against its monitoring demands and hearing risks with the oncology team. With the cream, improvement was gradual. Some women noticed slower regrowth within four to eight weeks, but in trials only about a third saw marked improvement after six months, compared with about 8% using an inactive cream. Shaving, plucking or other hair removal still continued. If no change appeared after six months, the cream was stopped. Hair growth returned to its earlier pattern within about eight weeks of stopping.

Questions to Ask Your Doctor

  1. 1.How much might Iwilfin lower my child's chance of relapse, and how certain is that estimate given how it was studied?
  2. 2.How often will hearing, blood counts and liver tests be checked, and what results would lead to a dose change or a pause?
  3. 3.Who should we call about a fever or new hearing problems, and what should we do after hours?
  4. 4.What birth control and breastfeeding precautions apply to us during treatment and afterward?
  5. 5.Now that Vaniqa is discontinued in the US, what other options make sense for my unwanted facial hair, and should we look for an underlying cause?

Last reviewed • Oct 2026

Educational content, not medical advice.